• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用蛋白质-蛋白质相互作用预测指导竞争性结合测定:HER2-亲和体应用案例

Guiding Competitive Binding Assays Using Protein-Protein Interaction Prediction: The HER2-Affitin Use Case.

作者信息

Ranaudo Anna, Cosentino Ugo, Greco Claudio, Moro Giorgio, Maiocchi Alessandro, Moroni Elisabetta

机构信息

Department of Earth and Environmental Sciences, University of Milano-Bicocca, Piazza della Scienza 1, 20126 Milan, Italy.

Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy.

出版信息

ACS Omega. 2024 Dec 5;9(50):49522-49529. doi: 10.1021/acsomega.4c07317. eCollection 2024 Dec 17.

DOI:10.1021/acsomega.4c07317
PMID:39713642
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11656212/
Abstract

Affitins are a class of small artificial proteins, designed as alternatives to antibodies for therapeutic, diagnostic, and biotechnological applications. Recent patents by Bracco Imaging S.p.A have demonstrated the potential of two engineered affitins for designing imaging probes to detect and monitor human epidermal growth-factor receptor 2 (HER2) levels . Targeting HER2 is critical, as its overexpression is linked to poor prognosis of several cancer diseases, making it a key marker for treatment strategies and diagnostic tools. Interestingly, these affitins do not compete with the commonly used monoclonal antibodies trastuzumab and pertuzumab for HER2 binding sites, allowing their concurrent use and making them suitable for imaging or diagnostic purposes. Since these two affitins compete for the same yet unidentified binding site on HER2, structural insights into these interactions are essential for facilitating the design and development of more effective diagnostic tools and treatments. In this study, we used protein-protein docking and molecular dynamics simulations to model the binding of these affitins to HER2. The stability of the predicted complexes was quantified by using the DockQ parameter, a widely used metric for evaluating protein-protein docking predictions. The docking poses were then compared with HER2 sites likely to interact with a protein partner, as predicted by the matrix of local coupling energies method. The combination of these two computational methods allowed for the identification of the most likely docking poses. Comparative analysis with HER2-protein complexes from the Protein Data Bank suggests that both affitins may bind HER2 at the same epitopes as an antibody fragment and an affibody. These findings indicate that targeted competitive binding assays could efficiently reduce the experimental efforts to map the HER2-affitin interactions. The computational approach proposed in this study not only provides insights into this specific case but also establishes a robust framework applicable for facilitating the structural modeling and interaction prediction of other affitin-protein systems.

摘要

亲合素是一类小型人工蛋白质,被设计作为抗体的替代品,用于治疗、诊断和生物技术应用。百时美施贵宝公司最近的专利证明了两种工程亲合素在设计成像探针以检测和监测人表皮生长因子受体2(HER2)水平方面的潜力。靶向HER2至关重要,因为其过表达与几种癌症疾病的不良预后相关,使其成为治疗策略和诊断工具的关键标志物。有趣的是,这些亲合素不会与常用的单克隆抗体曲妥珠单抗和帕妥珠单抗竞争HER2结合位点,从而允许它们同时使用,并使其适用于成像或诊断目的。由于这两种亲合素竞争HER2上相同但尚未确定的结合位点,因此对这些相互作用的结构洞察对于促进更有效的诊断工具和治疗方法的设计和开发至关重要。在本研究中,我们使用蛋白质-蛋白质对接和分子动力学模拟来模拟这些亲合素与HER2的结合。通过使用DockQ参数对预测复合物的稳定性进行量化,DockQ参数是一种广泛用于评估蛋白质-蛋白质对接预测的指标。然后将对接姿势与通过局部耦合能量矩阵方法预测的可能与蛋白质伴侣相互作用的HER2位点进行比较。这两种计算方法的结合使得能够识别最可能的对接姿势。与蛋白质数据库中HER2-蛋白质复合物的比较分析表明,两种亲合素可能在与抗体片段和亲和体相同的表位结合HER2。这些发现表明,靶向竞争性结合试验可以有效地减少绘制HER2-亲合素相互作用图谱的实验工作量。本研究中提出的计算方法不仅为这一特定案例提供了见解,还建立了一个稳健的框架,适用于促进其他亲合素-蛋白质系统的结构建模和相互作用预测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13ab/11656212/e4f7b9cf3a45/ao4c07317_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13ab/11656212/75c813f61887/ao4c07317_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13ab/11656212/178daac351d2/ao4c07317_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13ab/11656212/1ebb172caf21/ao4c07317_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13ab/11656212/e4f7b9cf3a45/ao4c07317_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13ab/11656212/75c813f61887/ao4c07317_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13ab/11656212/178daac351d2/ao4c07317_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13ab/11656212/1ebb172caf21/ao4c07317_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/13ab/11656212/e4f7b9cf3a45/ao4c07317_0004.jpg

相似文献

1
Guiding Competitive Binding Assays Using Protein-Protein Interaction Prediction: The HER2-Affitin Use Case.利用蛋白质-蛋白质相互作用预测指导竞争性结合测定:HER2-亲和体应用案例
ACS Omega. 2024 Dec 5;9(50):49522-49529. doi: 10.1021/acsomega.4c07317. eCollection 2024 Dec 17.
2
Evaluation of docking procedures reliability in affitins-partners interactions.抗肌动蛋白与配体相互作用中对接程序可靠性的评估。
Front Chem. 2022 Dec 1;10:1074249. doi: 10.3389/fchem.2022.1074249. eCollection 2022.
3
Artificial binding proteins (Affitins) as probes for conformational changes in secretin PulD.作为促胰液素PulD构象变化探针的人工结合蛋白(亲和体)
J Mol Biol. 2008 Nov 28;383(5):1058-68. doi: 10.1016/j.jmb.2008.09.016. Epub 2008 Sep 16.
4
Characterization of Affitin proteolytic digestion in biorelevant media and improvement of their stabilities via protein engineering.生物相关介质中 Affitin 蛋白的酶解特性分析及通过蛋白质工程提高其稳定性。
Sci Rep. 2020 Nov 12;10(1):19703. doi: 10.1038/s41598-020-76855-z.
5
Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes.表皮生长因子受体2(HER2)进化保守基序的比较分析预测了新的潜在治疗性表位。
PLoS One. 2014 Sep 5;9(9):e106448. doi: 10.1371/journal.pone.0106448. eCollection 2014.
6
Switching an anti-IgG binding site between archaeal extremophilic proteins results in Affitins with enhanced pH stability.在古生菌嗜极端微生物蛋白之间切换抗IgG结合位点可产生具有增强pH稳定性的亲合素。
J Biotechnol. 2014 Dec 20;192 Pt A:123-9. doi: 10.1016/j.jbiotec.2014.10.006.
7
Affitins as robust tailored reagents for affinity chromatography purification of antibodies and non-immunoglobulin proteins.Affitins作为用于亲和色谱法纯化抗体和非免疫球蛋白蛋白质的强大定制试剂。
J Chromatogr A. 2016 Apr 8;1441:44-51. doi: 10.1016/j.chroma.2016.02.068. Epub 2016 Feb 27.
8
Potent and specific inhibition of glycosidases by small artificial binding proteins (affitins).小型人工结合蛋白(亲和素)对糖苷酶的强效特异性抑制作用。
PLoS One. 2014 May 13;9(5):e97438. doi: 10.1371/journal.pone.0097438. eCollection 2014.
9
Whole-bacterium ribosome display selection for isolation of highly specific anti-Staphyloccocus aureus Affitins for detection- and capture-based biomedical applications.全菌核糖体展示筛选技术用于分离高特异性抗金黄色葡萄球菌亲和素,以应用于检测和捕获为基础的生物医学领域。
Biotechnol Bioeng. 2019 Aug;116(8):1844-1855. doi: 10.1002/bit.26989. Epub 2019 May 15.
10
Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.HER2-曲妥珠单抗-帕妥珠单抗复合物的冷冻电镜结构。
PLoS One. 2019 May 1;14(5):e0216095. doi: 10.1371/journal.pone.0216095. eCollection 2019.

引用本文的文献

1
Investigating and evaluating potential antigen binding sites for monoclonal anti-HER2 antibodies: The LightDock approach.研究和评估抗HER2单克隆抗体的潜在抗原结合位点:LightDock方法。
Comput Struct Biotechnol J. 2025 Jun 3;27:2515-2525. doi: 10.1016/j.csbj.2025.06.001. eCollection 2025.

本文引用的文献

1
Evaluation of docking procedures reliability in affitins-partners interactions.抗肌动蛋白与配体相互作用中对接程序可靠性的评估。
Front Chem. 2022 Dec 1;10:1074249. doi: 10.3389/fchem.2022.1074249. eCollection 2022.
2
UniProt: the Universal Protein Knowledgebase in 2023.UniProt:2023 年的通用蛋白质知识库。
Nucleic Acids Res. 2023 Jan 6;51(D1):D523-D531. doi: 10.1093/nar/gkac1052.
3
Native or Non-Native Protein-Protein Docking Models? Molecular Dynamics to the Rescue.天然或非天然蛋白质-蛋白质对接模型?分子动力学来拯救。
J Chem Theory Comput. 2021 Sep 14;17(9):5944-5954. doi: 10.1021/acs.jctc.1c00336. Epub 2021 Aug 3.
4
Computationally-guided design and affinity improvement of a protein binder targeting a specific site on HER2.针对HER2上特定位点的蛋白质结合剂的计算辅助设计与亲和力改进
Comput Struct Biotechnol J. 2021 Feb 27;19:1325-1334. doi: 10.1016/j.csbj.2021.02.013. eCollection 2021.
5
New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab.深入了解 HER2 靶向治疗的亲和蛋白:超越曲妥珠单抗。
Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188448. doi: 10.1016/j.bbcan.2020.188448. Epub 2020 Oct 9.
6
Performance and Its Limits in Rigid Body Protein-Protein Docking.刚体蛋白质-蛋白质对接的性能及其限制。
Structure. 2020 Sep 1;28(9):1071-1081.e3. doi: 10.1016/j.str.2020.06.006. Epub 2020 Jul 9.
7
Targeted therapeutic options and future perspectives for HER2-positive breast cancer.针对 HER2 阳性乳腺癌的靶向治疗选择和未来展望。
Signal Transduct Target Ther. 2019 Sep 13;4:34. doi: 10.1038/s41392-019-0069-2. eCollection 2019.
8
Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.HER2-曲妥珠单抗-帕妥珠单抗复合物的冷冻电镜结构。
PLoS One. 2019 May 1;14(5):e0216095. doi: 10.1371/journal.pone.0216095. eCollection 2019.
9
Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer.曲妥珠单抗和帕妥珠单抗靶向HER2阳性乳腺癌的作用及协同作用机制
Cancers (Basel). 2018 Sep 20;10(10):342. doi: 10.3390/cancers10100342.
10
Nanofitin as a New Molecular-Imaging Agent for the Diagnosis of Epidermal Growth Factor Receptor Over-Expressing Tumors.纳米适配体作为一种新型分子成像剂用于诊断表皮生长因子受体过表达肿瘤
Bioconjug Chem. 2017 Sep 20;28(9):2361-2371. doi: 10.1021/acs.bioconjchem.7b00374. Epub 2017 Sep 12.